Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients: The STOP-FLU trial.

Publication

Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients: The STOP-FLU trial.

Journal Paper/Review - Aug 16, 2023

Mombelli Matteo, Neofytos Dionysios, Huynh-Do Uyen, Sánchez-Céspedes Javier, Stampf Susanne, Golshayan Délaviz, Dahdal Suzan, Stirnimann Guido, Schnyder Aurelia, Garzoni Christian, Venzin Reto M, Magenta Lorenzo, Schönenberger Melanie, Walti Laura N, Hirzel Cédric, Munting Aline, Dickenmann Michael, Koller Michael, Aubert John-David, Steiger Jürg, Pascual Manuel, Müller Thomas F, Schuurmans Macé M, Berger Christoph T, Binet Françoise-Isabelle, Villard Jean, Müller Nicolas J., Egli Adrian, Cordero Elisa, Van Delden Christian, Manuel Oriol, Swiss Transplant Cohort Study

Citation

Mombelli M, Neofytos D, Huynh-Do U, Sánchez-Céspedes J, Stampf S, Golshayan D, Dahdal S, Stirnimann G, Schnyder A, Garzoni C, Venzin R, Magenta L, Schönenberger M, Walti L, Hirzel C, Munting A, Dickenmann M, Koller M, Aubert J, Steiger J, Pascual M, Müller T, Schuurmans M, Berger C, Binet F, Villard J, Müller N, Egli A, Cordero E, Van Delden C, Manuel O, Swiss Transplant Cohort Study. Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients: The STOP-FLU trial. Clin Infect Dis 2023

Type

Journal Paper/Review (English)

Journal

Clin Infect Dis 2023

Publication Date

Aug 16, 2023

Issn Electronic

1537-6591

Brief description/objective

The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so that new vaccination strategies are needed in this population.